View Older Stories View More Recent Stories
-
Shares of this mega-cap pharma stock could outperform soon: Goldman Sachs
-
Eli Lilly shares rise as weight-loss drug receives China approval
-
Eli Lilly & Co. (LLY) option implied volatility after Roche reports weight loss pill data.
-
Midday movers: Nvidia, TSMC, Five Below, Spirit Airlines and Eli Lilly fall
-
Eli Lilly, Novo Nordisk fall as Roche's rival weight loss drug shows promise
-
Eli Lilly & Co. (LLY) call put ratio 2.4 calls to 1 put as share price down 2.6%
-
Eli Lilly (LLY) PT Raised to $1,100 at UBS
-
Berenberg lifts its global obesity market sales forecasts to $150B by 2035
-
Novo Nordisk (NVO), Others Decline After Pfizer (PFE) Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron
-
Eli Lilly & Co. (LLY) Announces CFO Resignation
-
Midday movers: Nvidia, Eli Lilly rise; BP, Novo Nordisk fall
-
Intel, Nvidia, Eli Lilly rise premarket; BP, Novo Nordisk fall
-
Novo Nordisk stock slips as Eli Lilly’s obesity drug results in faster weight loss
-
BMO Capital reiterates Eli Lilly (LLY) at Outperform on Morphic deal, 'a positive for Lilly shares'
-
Eli Lilly & Co. (LLY) to Acquire Morphic (MORF) for $57/sh Cash or $3.2B
-
Eli Lilly, Novo Nordisk shares fall as Ozempic, Wegovy tied to rare cases of vision loss
-
Ozempic Linked to Rare Cases of Vision Loss in Harvard Study - Bloomberg (NVO)
-
Pharma selloff overdone: JPMorgan
-
Stocks expected to have increasing option volume: LLY NOV PARA STZ
-
Eli Lilly & Co. (LLY) call put ratio 1.4 calls to 1 put after USAToday editorial
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
-
Morgan Stanley on Eli Lilly (LLY): 'we expect LLY shares to trade flat to slightly up'
-
Biogen (BIIB) trades lower after after Lilly's Alzheimer's drug is approved
-
Eli Lilly & Co. (LLY) Announces FDA Approval of Kisunla to Treat Early Symptomatic Alzheimer's Disease
-
Midday movers: Tesla, Rivian rise; Novo Nordisk, Pure Storage fall
-
Eli Lilly & Co. (LLY) call put ratio 1 call to 1.2 puts with focus on August 870 and 890 calls
-
Novo Nordisk, Eli Lilly stock slides after Biden op-ed calls for lower Ozempic, Wegovy Prices
-
Biden Says Novo Nordisk (NVO) Must Cut Ozempic, Wegovy Prices
-
Radionetics Oncology Enters Into Strategic Agreement With Lilly (LLY)
-
Eli Lilly & Co. (LLY) option implied volatility flat as share price near record high
-
Eli Lilly & Co. (LLY) collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria
-
Eli Lilly (LLY) PT Raised to $1,000 at Truist Securities
-
Midday movers: Apple, Eli Lilly rise; Coinbase falls
-
Eli Lilly & Co. (LLY) Declares $1.30 Quarterly Dividend; 0.6% Yield
-
ResMed, Inspire Medical slump after Lilly's positive Zepbound data; Citi downgrades
-
ResMed (RMD), Inspire Medical (INSP) sink following Lilly's sleep apnea results
-
Eli Lilly's (LLY) tirzepatide reduced obstructive sleep apnea (OSA) severity
-
Eli Lilly & Co. (LLY) 30-day option implied volatility flat
-
Eli Lilly & Co. (LLY) option IV near lower end of range
-
Eli Lilly & Co. (LLY) option IV flat as share price near record high
-
Popular stocks with increasing volume: ORCL LLY XOM GME SQ T MS SLB BAC AFRM
-
Midday movers: Coinbase, Yext fall; Apple, GM rise
-
Barclays Reiterates Overweight Rating on Eli Lilly (LLY)
-
FDA Panel Votes 11-0 Lilly's (LLY) Drug's Benefits Outweigh Risks - Bloomberg
-
Top pharma stocks to own in 2024 – Citi
-
Why BMO remains bullish on Eli Lilly (LLY) stock
-
Could Eli Lilly & Co. (LLY) be the first $1trn biopharma stock?
-
7 Themes to watch in 2024
-
Eli Lilly, UPS ahead, SoftBank's surprise loss - what's moving markets
-
Wall Street ticks higher, but chip stocks tumble
